Retatrutide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A synthetic triple-hormone peptide (GLP-1, GIP, glucagon) marketed for record-setting weight loss and metabolic improvement. Human evidence is strong: major weight loss, liver fat reduction, and blood sugar gains, though secondary benefits are less certain. GI side effects are common, long-term safety data are limited, and a theoretical thyroid tumor risk applies to the class. Not FDA-approved; most supply is unregulated research-grade material.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Retatrutide (LY3437943) is a first-in-class triple-hormone receptor agonist developed by Eli Lilly that simultaneously activates the GIP, GLP-1, and glucagon receptors. Administered as a once-weekly subcutaneous injection, it has produced the largest weight reductions ever recorded in obesity drug trials — up to 24.2% at 48 weeks in Phase 2 and 28.7% at 68 weeks in Phase 3. It is also being studied for type 2 diabetes, fatty liver disease (MASLD), knee osteoarthritis, and obstructive sleep apnea.
How it works in the body
A 'triple G' agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. GLP-1 suppresses appetite and improves blood sugar. GIP enhances the GLP-1 effect and may directly reduce fat storage. Glucagon increases energy expenditure and fat burning in the liver. The triple action produces dramatic weight loss.
Research overview
Retatrutide is the most advanced triple GIP/GLP-1/glucagon receptor agonist in clinical development. Its Phase 1b proof-of-concept trial in 72 people with type 2 diabetes (Urva et al., Lancet 2022) demonstrated safety and ~10% weight reduction at 12 mg over 12 weeks. Two landmark Phase 2 trials were published in 2023: Jastreboff et al. (NEJM, n=338 with obesity) showed dose-dependent weight loss up to 24.2% at 48 weeks with the 12 mg dose, with the weight loss curve still declining and no plateau observed; and Rosenstock et al. (Lancet, n=281 with T2D) showed HbA1c reductions up to 2.02% and weight loss up to 16.9% at 36 weeks. A MASLD substudy (Sanyal et al., Nature Medicine 2024, n=98) demonstrated liver fat reductions of 82-86% at the 8-12 mg doses, with 86% achieving normal liver fat levels at 24 weeks. The Phase 3 TRIUMPH program launched in 2023 and encompasses 8+ trials enrolling over 5,800 participants. TRIUMPH-4 (n=445, knee OA) was the first Phase 3 readout in December 2025, showing 28.7% weight loss and 75.8% pain reduction at 68 weeks.
Who researches Retatrutide?
Commonly researched by
People researching weight management options
Studied for effects on body composition, appetite regulation, or metabolic rate.
People exploring muscle growth and performance
Researched for potential effects on lean mass, strength, or athletic performance.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
People researching cardiovascular health
Studied for effects on heart function, blood pressure, or vascular health.
People researching blood sugar regulation
Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.
Important considerations for
Those with Personal/family history of MTC
AbsoluteTriple GLP-1/GIP/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.
Those with History of pancreatitis
HighGLP-1 component carries pancreatitis risk.
Those with Severe gastroparesis
HighGLP-1 component significantly slows gastric emptying.
Those who are pregnant or breastfeeding
AbsoluteInvestigational — no reproductive safety data.
Safety & interactions
Do not use if
Personal/family history of MTC
AbsoluteTriple GLP-1/GIP/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.
History of pancreatitis
HighGLP-1 component carries pancreatitis risk.
Severe gastroparesis
HighGLP-1 component significantly slows gastric emptying.
General cautions
Pregnancy
AbsoluteInvestigational — no reproductive safety data.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(7)
Rated by level of concern
Gastrointestinal adverse events
HighPMID 37366315; PMID 37385280; PMID 42250575
Dysesthesia (altered skin sensation)
ModerateLilly TRIUMPH-4 topline report: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
Dose-dependent increase in heart rate
ModeratePMID 37366315; NCT06383390
Pancreatitis (rare)
LowPMID 40291085; PMID 37385280 (class-based inference)
Gallbladder events (cholelithiasis)
ModerateClass evidence + weight-loss magnitude (PMID 37366315); retatrutide-specific rates unpublished
Thyroid C-cell tumor risk (GLP-1 class warning)
TheoreticalGLP-1 receptor agonist class labeling (FDA); no retatrutide-specific human data
Limited long-term safety data
HighNCT05929066; NCT06383390; PMID 41090431
Interaction summary(8)
Rated by direction with this peptide
Insulin and sulfonylureas
CautionModerateAdding retatrutide's glucose-lowering effect to insulin or an insulin secretagogue meaningfully raises hypoglycemia risk and generally requires pre-emptive down-titration of the background agent, as is standard across the incretin class; notably, no severe hypoglycemia occurred in the Phase 2 or Phase 3 T2D trials where background therapy was managed per protocol.
PMID 37385280 (Lancet 2023); PMID 42250575 (TRANSCEND-T2D-1); GLP-1 class labeling
Narrow-therapeutic-index oral drugs (warfarin, levothyroxine, antiepileptics)
CautionLowDelayed gastric emptying can alter the rate and extent of oral absorption, and Lilly ran a dedicated Phase 1 DDI cocktail study of midazolam, warfarin and caffeine with retatrutide (NCT05445232, completed Feb 2023) — results are not publicly posted, so monitoring (e.g. INR, TSH) during dose escalation is prudent rather than evidence-mandated.
NCT05445232; https://clinicaltrials.gov/study/NCT05445232
Anesthesia and procedural sedation
CautionModerateDelayed gastric emptying can leave retained gastric contents despite standard fasting, creating aspiration risk during general anesthesia or deep sedation; anesthesiology guidance for GLP-1 receptor agonists advises holding weekly agents before elective procedures, and retatrutide's triple agonism gives no reason to expect less gastric slowing.
ASA guidance on GLP-1 receptor agonists (class-based); PMID 37366315 (gastric effects)
Other incretin agonists (semaglutide, tirzepatide, liraglutide)
CautionModerateConcomitant use has never been studied and offers no expected additive benefit while increasing GI adverse event, heart-rate and hypoglycemia risk; Lilly's own Phase 3 program treats these as alternatives, not partners (retatrutide vs tirzepatide, NCT06662383; vs semaglutide, TRANSCEND-T2D-2, NCT06260722).
NCT06662383; NCT06260722
Antihypertensives and diuretics
CautionLowRetatrutide lowers systolic blood pressure by roughly 10 mmHg on its own, so existing antihypertensives may need down-titration to avoid hypotension, and the combination of diuretics with vomiting or diarrhoea from GI adverse events can produce volume depletion and prerenal acute kidney injury.
PMID 40291085 (meta-analysis, SBP -9.88 mmHg)
Metformin and SGLT2 inhibitors
NeutralLowThese were permitted background therapies throughout the Phase 2 and Phase 3 type 2 diabetes programs with no interaction signal reported, making them the best-characterized safe co-medications; SGLT2 inhibitors do add an independent volume-depletion consideration during GI adverse events.
PMID 37385280; PMID 42250575
Oral contraceptives
CautionTheoreticalTirzepatide, the other GIP receptor agonist, carries a labeled interaction reducing oral contraceptive exposure and advises a non-oral backup method during initiation and dose escalation; retatrutide's shared GIP agonism and gastric-emptying effects make the same concern mechanistically plausible, but no retatrutide-specific contraceptive PK data have been published.
Tirzepatide (Mounjaro/Zepbound) FDA label, class-based extrapolation; no retatrutide-specific data
Beta-blockers (metoprolol)
CautionTheoreticalLilly completed a dedicated Phase 1 study of retatrutide's effect on metoprolol pharmacokinetics (NCT06808802, completed April 2025) whose results are not yet public; separately, beta-blockade may blunt or offset retatrutide's dose-dependent heart-rate rise, which is a pharmacodynamic overlap rather than a demonstrated adverse interaction.
NCT06808802; https://clinicaltrials.gov/study/NCT06808802
Known risks(7)
Gastrointestinal adverse events
Mild to ModerateNausea (38-43%), diarrhea (33-35%), vomiting (20-21%), constipation (22-25%) at the higher doses in Phase 3. Dose-related; partially mitigated by slower dose escalation.
Dysesthesia (altered skin sensation)
MildNew Phase 3 finding: 8.8% and 20.9% in the two highest-dose arms vs 0.7% placebo in TRIUMPH-4. Generally mild.
Dose-dependent increase in heart rate
Mild to ModerateHeart rate increased 5-10 bpm, peaking around week 24. Consistent with GLP-1 class.
Pancreatitis (rare)
Serious / RareAcute pancreatitis reported in ~0.4% of Phase 2 participants. Consistent with GLP-1 class risk. Monitor lipase/amylase.
Gallbladder events (cholelithiasis)
Moderate~1.1% of retatrutide patients vs 0% placebo in Phase 2. Rapid weight loss is a known gallstone risk factor.
Thyroid C-cell tumor risk (GLP-1 class warning)
TheoreticalAll GLP-1 agonists carry a class precaution based on rodent thyroid C-cell tumors. Not confirmed in humans but expected as boxed warning if approved.
Limited long-term safety data
Lilly has reported treatment through 104 weeks in a selected TRIUMPH-1 extension cohort; long-term safety, including cardiovascular, cancer, and bone density effects, remains incompletely characterized.
Drug interactions(5)
Insulin and insulin secretagogues
May increase hypoglycemia risk. Dose adjustments of diabetes medications likely required.
Other GLP-1 or incretin-based agonists
Co-administration not recommended — overlapping mechanisms, additive GI side effects.
Oral medications with narrow therapeutic index (warfarin, digoxin, levothyroxine)
Slowed gastric emptying may alter absorption. Monitor levels during dose escalation.
Oral contraceptives
Delayed gastric emptying may reduce absorption. Backup contraception advised during dose escalation.
Antihypertensive medications
Retatrutide reduced systolic BP by up to 14.0 mmHg. May require dose reduction to avoid hypotension.
Research & benefits
Evidence base
- Evidence Level
- Strong Evidence
- Total Studies
- 12
- Human Participants
- 7000
Phase 2 results published in NEJM, Lancet, and Nature Medicine. Phase 3 TRIUMPH program has 8+ trials enrolling 5,800+ participants. Five positive Phase 3 studies reported: TRIUMPH-1, -2, -3, -4 and TRANSCEND-T2D-1. Not yet FDA-approved.
Researched for(6)
Rated by confidence in the evidence
Record-setting weight loss (up to 24.2% at 48 weeks Phase 2; 28.7% at 68 weeks Phase 3)
HighConfirmed in a Phase 2 randomized trial; the higher Phase 3 figures are unpublished company data.
PMID 37366315 (N Engl J Med 2023, Phase 2); NCT05929066 / NCT05931367 (Phase 3, topline only); https://pubmed.ncbi.nlm.nih.gov/37366315/
Dramatic liver fat reduction — 86% of MASLD patients achieved normal liver fat at 24 weeks
HighPhase 2a trial: 86% on the highest dose reached normal liver fat by week 24.
PMID 38858523 (Nat Med 2024, Sanyal et al., phase 2a retatrutide MASLD trial); https://pubmed.ncbi.nlm.nih.gov/38858523/
Substantial HbA1c reduction in type 2 diabetes (up to 2.02% at 24 weeks)
HighPhase 2 randomized trial showed a 2.02% HbA1c drop, later confirmed in a 2026 Phase 3 trial.
PMID 37385280 (Lancet 2023); PMID 42250575 (Lancet 2026, TRANSCEND-T2D-1)
Significant osteoarthritis pain relief (75.8% WOMAC pain score reduction)
MediumA Phase 3 trial measured this outcome, but the 75.8% figure is from unpublished company reporting.
NCT05931367; PMID 41090431 (Diabetes Obes Metab 2026, TRIUMPH design paper); Lilly topline (unpublished)
Cardiovascular risk marker improvements (blood pressure, lipids, hsCRP)
HighMeta-analysis and trials show blood pressure and lipid gains; preliminary cardiovascular event analyses have been reported, without demonstrated benefit.
PMID 40291085 (Proc Bayl Univ Med Cent 2025, meta-analysis); PMID 37366315; NCT06383390
Favorable body composition — preferential fat loss over lean mass
HighA Phase 2 body-composition substudy found fat loss dominates, though lean mass loss is still notable.
PMID 40609566 (Lancet Diabetes Endocrinol 2025)
Benefits(6)
Record-setting weight loss (up to 24.2% at 48 weeks Phase 2; 28.7% at 68 weeks Phase 3)
Phase 2 (Jastreboff, NEJM 2023, n=338): 12 mg achieved 24.2% at 48 weeks. Phase 3 TRIUMPH-4 (n=445): 12 mg achieved 28.7% at 68 weeks.
Dramatic liver fat reduction — 86% of MASLD patients achieved normal liver fat at 24 weeks
Sanyal et al., Nature Medicine 2024, n=98: 12 mg reduced liver fat by 82-86%; 86% achieved normal levels (<5%) vs 0% placebo.
Substantial HbA1c reduction in type 2 diabetes (up to 2.02% at 24 weeks)
Rosenstock et al., Lancet 2023, n=281: 12 mg reduced HbA1c by 2.02% at 24 weeks, exceeding dulaglutide.
Significant osteoarthritis pain relief (75.8% WOMAC pain score reduction)
TRIUMPH-4 Phase 3 (n=445): 9 mg reduced WOMAC pain by 75.8% vs 40.3% placebo at 68 weeks.
Cardiovascular risk marker improvements (blood pressure, lipids, hsCRP)
TRIUMPH-4: 12 mg lowered systolic BP by 14.0 mmHg with reductions in non-HDL cholesterol, triglycerides, and hsCRP.
Favorable body composition — preferential fat loss over lean mass
Body composition substudy (Lancet Diabetes & Endocrinology 2025; 189 enrolled, 155 with baseline DXA, 103 with both scans): 8 mg reduced total fat mass by 26.1% vs 4.5% placebo.
Key studies(4)
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Phase 2 RCTn=33848 weeksJastreboff AM, Kaplan LM, Frias JP, et al.
New England Journal of Medicine
2023
Dose-dependent weight loss: 24.2% at 12 mg vs 2.1% placebo at 48 weeks. No plateau observed. 100% of 12 mg patients achieved >=5% weight loss.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
Phase 2 RCTn=28136 weeksRosenstock J, Frias JP, Rodbard HW, et al.
The Lancet
2023
HbA1c reduction of 2.02% at 24 weeks (12 mg) vs -0.01% placebo. Weight loss up to 16.94% at 36 weeks.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Phase 2a RCT (substudy)n=9848 weeksSanyal AJ, Kaplan LM, Frias JP, et al.
Nature Medicine
2024
Liver fat reduced by 82-86% at 8-12 mg doses. 86% achieved normal liver fat (<5%) at 12 mg vs 0% placebo at 24 weeks.
TRIUMPH-4: Retatrutide in Adults with Obesity and Knee Osteoarthritis (Phase 3)
Phase 3 RCTn=44568 weeksEli Lilly and Company
Eli Lilly press release / ClinicalTrials.gov
2025
28.7% weight loss at 12 mg; 75.8% WOMAC pain reduction at 9 mg. Systolic BP reduced by 14.0 mmHg.
What research suggests over time
Weeks 2-4
Phase 2 NEJM 2023Rapid appetite reduction and early weight loss as dose escalation begins.
Months 2-3
Phase 2 NEJM 2023~9-15% body weight reduction at the higher trial doses by week 12-24.
Long-term
Phase 2/3 RCTMean 24.2% weight loss at 48 weeks (highest-dose arm, Phase 2); 28.7% at 68 weeks in Phase 3 TRIUMPH-4.
Regulation & availability
Why researchers look at it
Retatrutide has produced the most dramatic weight loss results ever in obesity drug trials — 28.7% in Phase 3 — by adding glucagon receptor activation on top of GIP/GLP-1. Its MASLD data (86% liver fat normalization) is unprecedented. With Phase 3 results in 2026 and potential FDA approval in 2027, it is the most closely watched obesity drug in development.
- Estimated cost
- Not yet available — Phase 3 trials ongoing (Eli Lilly)
- FDA status
- Retatrutide is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding. Lilly plans a Biologics License Application submission in Q1 2027. Approval timing is unconfirmed.
- WADA status
- Not explicitly listed by name but effectively prohibited under S0 (Non-Approved Substances) as an unapproved investigational drug.
- Prescribability
- No — Investigational (Phase 3 ongoing)
- Availability
- Access limited to clinical trial enrollment.
International status
EU
Phase 3 trials
US
Phase 3 trials (Eli Lilly)
Worldwide
Investigational — not yet approved anywhere
Regulatory timeline(9)
- 2022-11Phase 1b results published in The Lancet — ~10% weight loss at 12 mg in 12 weeks
- 2023-06Phase 2 obesity results published in NEJM — up to 24.2% weight loss at 48 weeks
- 2023-06Phase 2 T2D results published in The Lancet — HbA1c -2.02%, weight -16.9% at 36 weeks
- 2023-H2Phase 3 TRIUMPH program initiated — 8+ trials, 5,800+ participants
- 2024-06MASLD results published in Nature Medicine — 86% liver fat normalization
- 2025-12TRIUMPH-4 Phase 3 topline results — 28.7% weight loss, 75.8% OA pain reduction
- 2026-03TRANSCEND-T2D-1 Phase 3 results — HbA1c -1.7 to -2.0%, 16.8% weight loss
- 2026-05-21Positive TRIUMPH-1 topline results announced.
- 2027-2028 (expected)Potential FDA approval
Sources & FAQs
Research sources(5)
Frequently asked questions(4)
How does retatrutide compare to semaglutide and tirzepatide?
Retatrutide activates three receptors (GIP, GLP-1, glucagon) vs one for semaglutide and two for tirzepatide. It has produced the largest weight reductions ever recorded: 28.7% at 68 weeks vs ~15% for semaglutide and ~22% for tirzepatide. The glucagon component adds energy expenditure and liver fat burning beyond the other drugs. No head-to-head trials exist.
When will retatrutide be available?
Phase 3 trials are reading out throughout 2025-2026. If positive, Lilly plans a BLA submission in Q1 2027; approval timing remains unconfirmed. It cannot legally be compounded or sold outside clinical trials.
Can retatrutide treat fatty liver disease?
Phase 2 data is extremely promising: 86% of MASLD patients achieved normal liver fat at the highest dose. A dedicated MASLD Phase 3 trial is part of the TRIUMPH program.
What are the main side effects?
GI symptoms are most common: nausea (38-43%), diarrhea (33-35%), vomiting (20-21%). A new Phase 3 finding was dysesthesia (altered skin sensation) in up to 21%. Slower dose escalation partially mitigates GI symptoms.